MBCProject_5953_T1_RNA
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.490
- ANDROGEN_RESPONSE+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- MYC_TARGETS_V1+0.390
- E2F_TARGETS+0.350
- G2M_CHECKPOINT+0.330
- SPERMATOGENESIS+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.230
- UV_RESPONSE_DN+0.220
- MITOTIC_SPINDLE+0.190
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.430
- INTERFERON_GAMMA_RESPONSE-0.380
- MYOGENESIS-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- KRAS_SIGNALING_DN-0.190
- ALLOGRAFT_REJECTION-0.160
- UV_RESPONSE_UP-0.150
- P53_PATHWAY-0.100
- TNFA_SIGNALING_VIA_NFKB-0.100
- DNA_REPAIR-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A1FM-01A-11R-A13Q-07 | — | B | 0.802 |
| 2 | R325 | — | — | 0.796 |
| 3 | TCGA-D8-A1XS-01A-11R-A14M-07 | — | B | 0.786 |
| 4 | SJEPD031129_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.769 |
| 5 | TCGA-96-7544-01A-11R-2045-07 | — | cohortSQ1 | 0.765 |
| 6 | SRR4195688 | — | — | 0.762 |
| 7 | MNG1179 | — | — | 0.757 |
| 8 | MBCProject_0946_T1_RNA | — | C | 0.749 |
| 9 | TCGA-UY-A78L-01A-12R-A33J-07 | — | — | 0.739 |
| 10 | TCGA-39-5034-01A-01R-1443-07 | — | cohortA3 | 0.730 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.410 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |